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Abstract
Because our beliefs regarding our individuality, autonomy, and personhood are intimately bound up with our brains, 
there is a public fascination with cerebral organoids, the “mini-brain,” the “brain in a dish”. At the same time, the 
ethical issues around organoids are only now being explored. What are the prospects of using human cerebral 
organoids to better understand, treat, or prevent dementia? Will human organoids represent an improvement on the 
current, less-than-satisfactory, animal models?  When considering these questions, two major issues arise. One is the 
general challenge associated with using any stem cell–generated preparation for in vitro modelling (challenges amplified 
when using organoids compared with simpler cell culture systems). The other relates to complexities associated with 
defining and understanding what we mean by the term “dementia.” We discuss 10 puzzles, issues, and stumbling blocks 
to watch for in the quest to model “dementia in a dish.”
Keywords
dementia, organoids, induced pluripotent stem cells, Alzheimer’s disease, neurodegeneration, cerebral, cortical, 
disease model
Introduction
Cerebral organoids (Fig. 1), or “mini-brains” as they are 
commonly referred to, are three-dimensional tissue struc-
tures that are generated in vitro (often from pluripotent 
stem cells) (Pașca 2018), containing different cell types 
of the brain, and representing the anatomical structures of 
the brain (Fig. 2). Organoids are used for disease model-
ling for dementia (summarized in Table 1); however, 
there are a number of important considerations. We out-
line the 10 big questions that impinge on the design and 
interpretation of experiments using cerebral organoids 
from dementia patients.
Question 1: How Do We Define 
Dementia? What Is Its True Burden?
Dementia is a syndrome that is caused by different neu-
rodegenerative diseases, including Alzheimer’s disease, 
Parkinson’s disease, Huntington’s disease (Silverberg 
and others 2018). Few people in medical research under-
estimate the prevalence of the disease on which they 
work; meanwhile prevalence and incidence rate esti-
mates are affected by comorbidity and misdiagnoses 
(van der Flier and Scheltens 2005). Coexisting uneasily 
with this is a public fear of losing one’s mind through 
dementia, of alarming (or alarmist) predictions of run-
away personal costs due to the basic loss of control and 
dignity that is central to dementia, and the economic 
costs confronting the health and aged care sys-
tems. Accurate figures are necessary so the health care 
system can estimate the burden of disease and plan for 
the personal and institutional cost of treatment. Accurate 
figures are also essential to determine if population-
based interventions are effective.
Dementia describes a syndrome where there is pro-
gressive loss of cognitive skills over time, sufficient to 
interfere with independent living. This can be due to one 
2 The Neuroscientist 00(0)
of several underlying causes, or to more than one cause 
acting together. During the normal process of ageing, 
many people lose cognitive skills, but for the majority 
this is not sufficient to cause more than inconvenience or 
anxiety. By contrast, by the age of 90, 28% of men and 
45% of women develop dementia, according to a popula-
tion study in the United States (Corrada and others 2008). 
Similar estimates come from other high-income coun-
tries, but it is not clear if the same applies in middle-
income countries that now are achieving an ageing profile 
similar to the United States or Australia, such as China 
and India.
We also do not have accurate information on whether 
the age-adjusted incidence of dementia is genuinely 
decreasing when compared to 20 years ago (Satizabal and 
others 2016; Seblova and others 2018; Wu and others 
2017). Addressing this problem is vitally important for 
obtaining accurate epidemiological estimates of inci-
dence, progression, and the impact of care. Drift in diag-
nostic criteria over time (Jack and others 2018) has made 
such comparisons difficult. The way in which the finan-
cial burden of care is allocated by disease also will affect 
the diagnoses that are offered (McPhail 2016). Defining 
dementia and its burden is important when considering 
using organoids as a disease model; if we are not able to 
define or accurately diagnose disease we could be study-
ing cells from people that do not represent dementia 
patients.
Question 2: What Is the True 
Etiology of Dementia?
Most research begins with a clinical assessment to 
determine whether a patient has dementia. Experienced 
geriatricians, psychiatrists, neurologists, and psycholo-
gists can distinguish dementia from other mental illness 
or delirium. However, differential diagnosis between 
the four common dementia etiologies is challenging. 
Alzheimer dementia (AD), vascular dementia (VD), 
dementia with Lewy Bodies (DLB), and frontotemporal 
lobar dementia (FTLD) share many clinical features, but 
different etiologies, and relying solely on clinical assess-
ment has limitations if all four are lumped together as 
“dementia.” It is particularly important to separate VD 
from the other causes of dementia, as it is often prevent-
able, has a major environmental component, and does 
not “progress” as Alzheimer disease does.
Furthermore, several age-related neurodegenerative 
diseases can coexist in the elderly brain (Boyle and others 
2018) and hence use of biomarkers for phenotyping will 
be limited unless all four major causes of dementia are 
considered. This rarely happens at present. Stem cells 
generated from research participants (invariably labelled 
with a single diagnosis) could have multiple background 
neuropathologies, potentially compromising both “dis-
ease” and “control” cell lines.
Given that a person with dementia may have a bio-
marker pattern indicating more than one etiology, the 
challenging question then becomes how to best define 
the “prime mover.” For AD, combining genetics (the 
presence of APOE4), biomarkers (amyloid-beta frag-
ment ratios in blood and/or cerebral spinal fluid), and 
imaging (amyloid as seen using positron emission 
tomography) is diagnostic (Jack and others 2018; 
Villemagne and others 2018). Similar multidisciplinary 
approaches are being developed to diagnose DLB and 
FTLD, incorporating genetic risk, biomarker assess-
ment, and imaging (Meeter and others 2017). The 
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diagnosis of VD relies primarily on neuroimaging 
(using magnetic resonance imaging) to reveal either 
macro- or microvascular disease. Given the advanced 
state of these technologies, any stem cell–related mod-
elling approach must start by demanding a high-quality 
diagnostic workup of the persons providing the donor 
cells. For data from organoids to be meaningful, we 
need to be able to label each with an accurate history, 
including types of dementia and staging.
Question 3: Comorbidity and Why Is 
Age the Biggest Risk Factor?
Most people with dementia are elderly. Many elderly 
people have comorbidities, such as hypertension, coro-
nary artery disease, depression, or diabetes. Vascular risk 
factors and related conditions that develop in later life, 
including cardiovascular disease, diabetes, hypertension, 
and stroke, are all associated with an increased risk of 
Figure 1. The experimental paradigm using cerebral organoids to investigate Alzheimer’s disease. (A) Alzheimer’s disease 
(AD) is the most prevalent form of dementia and is characterized by neuronal cell death to the cortex and hippocampus 
of the brain resulting in impaired memory, cognition, and behavior. The underlying molecular mechanisms that result in 
neurodegeneration remain to be defined, with patient-derived induced pluripotent stem cells (iPSCs) offering a biologically 
relevant model to better understand the biological basis of AD. The AD brain shows a reduced volume due to the loss of 
synapses and neurons. (B) During normal development pluripotent stem cells differentiate into multiple cell types of the body, 
including cells from the three germ layers, the ectoderm, mesoderm, and endoderm. Terminally differentiated cells, such as 
skin cells, can be reprogrammed to generate iPSCs that have the capacity to differentiate into multiple cell types of the body. 
(C) To model AD in a dish, patients donate cells (such as skin cells) that are reprogrammed into iPSCs. The iPSCs can then be 
differentiated into neurons or other cell types. The use of AD patient–derived iPSCs allows researchers to generate cells of a 
specific lineage, including neurons and glial cells, to characterize disease phenotypes that may be a result of the patient’s genetic 
makeup and to develop new therapeutics via drug screening. (D) Cerebral organoids are three-dimensional stem cell cultures 
that have the advantage over traditional two-dimensional culture approaches as they allow the stem cells to self-organize 
into structures, form signaling networks and develop cell-cell interactions that better mimic in vivo neurodevelopment. These 
three-dimensional culture systems allow us to better model and further interrogate the roles that different neural and glial cell 
types play in neurodegeneration. The cerebral organoids contain a mixture of neural cell types that represent the anatomical 
structure of the brain.
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dementia (Breteler 2000). Furthermore, it is not clear 
whether different morbidities combine in an additive or 
synergistic way to affect brain function (Abner and others 
2016). Is it valid to model dementia etiology without tak-
ing into account these major chronic diseases with known 
complex connections to brain function? Thoroughly char-
acterizing donors will require considering not only 
comorbidity but also issues beyond dementia-related his-
tory, including non–central nervous system systemic 
health. To address this, an accepted framework or set of 
guidelines developed by the research community, fund-
ing bodies, and regulators would vastly help in standard-
izing the information gathered per donor for the purposes 
of disease modeling.
Although research attention has, understandably, 
focused on genetic and environmental risk, and on diag-
nosis, the single biggest risk factor for all forms of 
dementia is age. Induced pluripotent stem cells (iPSCs) 
are thought to be the equivalent, in stage, to fetal cells; if 
they are aged in the laboratory, is this the equivalent of 
ageing in a person? Can organoids be used to study the 
mechanisms by which ageing contributes to dementia?
Question 4: Just How Much of the 
Risk of Alzheimer Dementia Is 
Genetic and What Is the Role of 
APOE4?
There are a very small number of families that are 
affected by Mendelian younger-onset forms of AD 
(YOAD, familial AD). Symptoms of dementia in YOAD 
often begin between 40 and 50 years of age due to a 
fully penetrant mutation in one of the APP, PSEN1, or 
PSEN2 genes (Goate and others 1991; Levy-Lahad and 
others 1995; Sherrington and others 1995). For these 
Figure 2. Generalized schematic of cerebral organoid differentiation based on Lancaster and Knoblich (2014). (A) Small 
molecule inhibitors are added to human pluripotent stem cells to drive differentiation toward a cortical phenotype. Scale 
bar = 200 µm. (B) Following neural induction, neural rossettes are harvested for three-dimensional culture as neurospheres. 
Scale bar = 200 µm. (C) Cortical neurospheres are cultured in suspension to allow for maturation and expansion. Following 
2 weeks, neurospheres are maintained for longer times to allow for further self-organization and differentiation. Cortical 
neurospheres self-organize into distinct structures. Neural rosettes observed in vitro during cerebral organoid culture 
(highlighted in the rectangle) represent the neural tube formation in vivo during human neurodevelopment. Scale bar = 200 µm. 
(D) Cerebral organoids are maintained for long-term culture allowing for neural differentiation that recapitulates human brain 
development, and continue to grow in size. Scale bar = 200 µm. Cerebral organoids can be cryosectioned and characterized by 
immunocytochemistry, using antibodies directed at specific neuronal and glial markers to show the heterogeneous populations of 
cells contained within an individual organoid. A representative example of a cerebral organoid derived from a healthy individual 
shows the nuclear stain, Hoechst, blue (E); the mature neuronal marker microtubule associated protein 2 (MAP2), green (F); the 
astrocyte marker glial fibrillary acidic protein (GFAP), red (G); the merged overlay (H; scale bar = 25 µm); and a magnified image 
to show the mix of neurons and astrocytes in the organoid (I; scale bar = 50 µm).
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families, the risk is genetic. However, the great majority 
of cases of Alzheimer dementia are late-onset (LOAD; 
>65 years of age), not Mendelian (although the disease 
“runs in families”), and influenced by more common 
genetic variants, notably those within the apolipoprotein 
E (APOE) gene (Strittmatter and others 1993) but also 
other genes (Fig. 3). The term “sporadic” is a misnomer; 
Alzheimer dementia is not sporadic, even if we do not 
yet understand all of the predetermining genetic and 
environmental risk factors.
Table 1. Summary of Organoid Models Used in Alzheimer’s Disease Research.
Summary Cell Line Days Matured Reference
The authors successfully recapitulated Alzheimer’s 
disease pathology, including Aβ aggregates and 
hyperphosphorylated tau in cerebral organoids. Choi and 
colleagues (2014) showed that inhibition of Aβ generation 
reduced Aβ pathology and tauopathy; glycogen synthase 
kinase 3 regulated Aβ-mediated tau phosphorylation.
ReN cell VM 
overexpressing 
human APP and PSEN1 
containing YOAD 
mutations
42–84 days Choi and others 
(2014)
The 3D neuronal model generated recapitulated both tau 
and amyloid pathology. β and γ-secretase inhibitors were 
more efficient in reducing Aβ levels in 2D than in 3D 
neuronal cultures and the response to drug treatment 
was highly variable among the different iPSC lines.
iPSCs derived from 
PBMCs of five LOAD 
patients
42–63 days Lee and others 
(2016)
Using iPSC-derived cerebral organoids AD 
phenotypes were observed, including Aβ aggregates, 
hyperphosphorylated tau, and endosome abnormalities. 
Patient-derived organoids with β- and γ-secretase 
inhibitors resulted in a significant reduction in Aβ and tau 
pathology.
iPSCs derived from four 
YOAD patients with 
APP duplication or 
PSEN1 mutation
60–100 days Raja and others 
(2016)
Cerebral organoids derived from YOAD and Down 
syndrome (DS) patients spontaneously developed 
structures reminiscent of Aβ plaques and NFTs over time. 
These structures were not observed in iPSCs derived 
from healthy controls, patients affected by Creutzfeldt-
Jakob disease or mouse embryonic stem cells and iPSCs.
iPSCs derived from a 
YOAD patient with a 
mutation in PSEN1 and 
a DS patient
30–110 days Gonzalez and 
others (2018)
APOE4 cerebral organoids demonstrated accumulation of 
Aβ and tau hyperphosphorylation after 6 months, whereas 
fAD organoids used in Raja and others (2016) showed 
pathology after 2 months. APOE4 alone was sufficient to 
induce AD pathology. APOE4 in LOAD organoids had 
significantly higher levels of Aβ after 6 months compared 
to age-matched APOE3 organoids. These findings provide 
evidence for the role of APOE4 in sAD; gene editing to 
APOE3 protected against AD pathology.
iPSC line derived from 
LOAD patient and 
healthy control. 
Used CRISPR/Cas9 
to convert APOE4 to 
APOE3 or vice versa.
180 days Lin and others 
(2018)
This study generated a novel 3D triculture system 
using a microfluidic platform for neurons, astrocytes, 
and microglia. There was increased Aβ, inflammatory 
cytokines, chemokines and hyperphosphorylated tau 
in the triculture system. The model showed microglial 
recruitment and neurotoxic properties, including pro-
inflammatory cytokine/chemokine release, axonal damage 
and nitric oxide release, which was proposed to damage 
neurons and astrocytes in culture. Knocking down Toll-
like receptor 4 (TLR4) protected against neuronal and 
astrocyte loss. The iPSC derived triculture replicated 
microglial recruitment and activation and neuronal and 
astrocyte loss.
ReN cell VM expressing 
APP containing YOAD 
mutations with 
both K670N/M671L 
(Swedish) and V717I 
(London), human 
microglia SV40 cell 
line, and SCR131 iPSC 
neural progenitors
21–70 days Park and others 
(2018)
Aβ secretion and accumulation was promoted by the 
chemical inducer Attin-5, which increased Aβ42 and Aβ42/
Aβ40 ratio.
iPSCs reprogrammed 
from CRL-2522 
fibroblasts
60–225 days Pavoni and 
others (2018)
Aβ = amyloid-β; DS = Down syndrome; LOAD = late-onset Alzheimer Dementia iPSCs = induced pluripotent stem cells; NFTs = neurofibrillary 
tangles; PBMCs = peripheral blood mononuclear cells; YOAD = younger-onset Alzheimer Dementi.
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The importance of APOE4 has been known for more 
than 25 years (Qian and others 2017; Spinney 2014). 
Approximately 25% of the population has one copy of 
APOE4, and approximately 2% is homozygous for this 
variant, but both APOE4 prevalence and its impact vary 
somewhat for different ethnic groups (Rajabli and others 
2018). Possession of one allele of APOE4 increases risk 
of developing AD threefold, while two copies of APOE4 
increases risk 15-fold, matching a co-dominant model. 
Healthy, non-AD adults with high levels of amyloid show 
higher levels of memory decline if they are APOE4 carri-
ers (Lim and others 2016; Thai and others 2015). 
Although APOE4 is the major genetic determinant for 
developing LOAD, around half of those with an APOE4 
allele will not develop dementia (Qian and others 2017). 
The impact of risk factor genes beyond APOE therefore 
needs to be considered. This has led to development of a 
polygenic risk score, which takes into account the contri-
butions of alleles of many genes, each with a small effect 
contributing to the risk of developing LOAD (Escott-
Price and others 2015). Some of the “minor risk genes” 
describe functions specific to neurons, such as synaptic 
processes and axonal transport, while others affect path-
ways in lipid metabolism and inflammation (Lambert and 
others 2013).
It is important to note that, unlike the Mendelian 
autosomal dominant mutations, APOE4 is a risk factor 
and is not fully penetrant. While it is usually assumed 
that this involves interactions with other genetic vari-
ants, it is still possible that genetics and lifestyle 
interact to lower or increase AD risk. The ethical issues 
regarding privacy, consent, data sharing, and risk of re-
identification associated with acquiring a full genetic 
profile from individuals can be a barrier to stem cell–
based studies. However, stem cell studies of dementia 
would be improved by knowledge of the full genetic 
profile of each donor; advanced molecular technolo-
gies, such as genome editing and single-cell RNA 
sequencing, should assist in assigning specific cell 
functions to particular combinations of risk variants.
Question 5: Are Protein Aggregates 
the Main Culprit?
The amyloid hypothesis (Hardy and Higgins 1992) was 
the first attempt to explain the relationship between the 
key pathological features of AD (beta-amyloid [Aβ] 
plaques and tau neurofibrillary tangles) and the develop-
ment of dementia. It argues for a central role for Aβ as the 
trigger for the key features of AD. It is based on three 
major findings: (1) that mutations in the amyloid precur-
sor protein (APP) gene itself, and in pathways associated 
with Aβ production, cause familial YOAD; (2) that there 
is a large amount of Aβ found in the brains of affected 
individuals; and (3) that persons with Down syndrome, 
who synthesize higher amounts of Aβ as the gene for Aβ 
is on chromosome 21, develop YOAD.
Although amyloid is important in AD, there is a grow-
ing view that the amyloid hypothesis is not complete 
(Makin 2018). Amyloid load does not correlate closely 
Figure 3. Genetic risk for Alzheimer’s disease. Mutations in APP, PSEN1, and PSEN2 that cause younger-onset AD (YOAD; also 
known as “familial AD”) are rare with the vast majority of genetic risk for late onset (LOAD; also known as “sporadic AD”) 
arising through common variants in multiple genes that each increase risk but which individually are not causative. Figure modified 
from Karch and Goate (2015).
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with cognitive loss (Hedden and others 2013), and recent 
trials that successfully removed amyloid from the brains 
of those with Alzheimer dementia did not have an impact 
on clinical progression (Wang and others 2017).
Two alternative explanations for the cause of AD 
focus, respectively, on the role of tau, or inflammation 
(Figure 4). Tau pathology occurs during ageing, start-
ing in the lateral entorhinal cortex (Braak and others 
2011). It is possible that amyloid catalyzes the spread 
of tau rather than directly inducing tau pathology. This 
model could potentially explain the “no going back” 
theory: once tau deposition is initiated, removing amy-
loid would not be effective at stopping AD progression 
(Jacobs and others 2018; Price and Morris 1999). A 
range of methods have been used to assess Aβ and tau 
“pathology” in cerebral organoids from AD patients 
and controls (Figure 5).
The suggestion that inflammation is a driver of cogni-
tive loss is supported by data demonstrating key roles for 
immune cells in controlling relevant normal brain func-
tion (Szepesi and others 2018). Many of the minor genes 
implicated in AD are associated with microglial or 
immune cell function, whether through modulation of 
inflammation or regulating non-inflammatory processes, 
such as synapse loss (Hong and others 2016a; Hong and 
others 2016b; Kinney and others 2018).
Figure 4. Summary of the amyloid, tau, and inflammation hypotheses for Alzheimer’s disease. Amyloid precursor protein 
(APP) is a membrane protein that is proteolyticaly cleaved by multiple enzymes. The non-amyloidgenic pathway proceeds 
when APP is cleaved by the activity of α-secretase (α-sec) to soluble APP α (sAPPα) and APP carboxy terminal fragment α 
(APP-CTFα), these products are cleaved by γ-secretase (γ-sec) to produce truncated Aβ (p3) and the cytoplasmic polypeptide 
named AICD. The amyloidgenic pathway occurs when APP undergoes cleavage by β-secretase (β-sec) to form sAPPβ and 
APP-CTFβ. These proteins are cleaved by γ-sec to form AICD and amyloid-β (Aβ). In YOAD, mutations in APP, PSEN1, and 
PSEN2 there is an increase in the 42-residue Aβ42, relative to Aβ40, which leads to an increase in Aβ oligomers and amyloid 
plaque formation (Thinakaran and Koo 2008). Tau binds to microtubules and is important in cytoskeletal function. In AD, tau 
is hyperphosphorylated resulting in cytoskeletal dysfunction. Hyperphosphorylated tau detaches from microtubules and forms 
paired helical filaments that aggregate and form neurofibrillary tangles (NFTs). Inflammation is hypothesized to contribute to 
cognitive loss in AD. Astrocytes and microglia are activated in the AD brain, releasing pro-inflammatory cytokines (e.g., tumor 
necrosis factor-α [TNFα], interleukin [IL]-1β, IL-6, interferon-γ [IFNγ]) and chemokines (e.g., MIP-1α and MIP-1β) resulting in 
neuronal death, either by directly damaging neurons or by failing in their normal function to clear aggregates from the brain (Azizi 
and others 2015). There are multiple underlying molecular pathways leading to AD; intersecting pathways between amyloid, tau, 
inflammation, and other processes contribute to a complex mechanism that drives neurodegeneration.
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Twenty-five years after it was first proposed, the amy-
loid hypothesis remains hotly debated, with many voices 
arguing for the need for new ideas (Makin 2018). 
However, there is no need to assume that there is only one 
player in the underlying molecular pathways leading to 
AD. Amyloid, tau, and inflammation (and other pro-
cesses) are best seen as interacting parts in a complex 
process that leads to dementia.
Rarer diseases than AD that are characterized by 
aggregates of proteins other than amyloid can lead to 
neurodegeneration in the absence of amyloid plaques 
(non-Alzheimer dementias), such as tau aggregation in 
age-related tauopathy, progressive supranuclear palsy, 
or dementia with Lewy bodies and TDP-43 aggrega-
tion in hippocampal sclerosis or frontotemporal lobar 
dementia (Nelson and others 2016). TDP-43 pathology 
biomarkers are unreliable (Steinacker and others 
2019), while tau imaging tools remain problematic in 
terms of off-target (non-tau) binding and a reduced 
ability to identify non-AD tau aggregation (Leuzy and 
others 2019). Developing reliable biomarkers is impor-
tant for accurate disease models and to understand the 
link between aggregation of certain proteins and 
dementia.
Figure 5. Assessing Aβ and tau pathology in human brain organoids. (A) The localization of Aβ and phosphorylated tau (p-tau) 
has been visualized in organoids by immunocytochemistry (Choi and others 2014; Gonzalez and others 2018; Lee and others 
2016; Lin and others 2018; Park and others 2018; Pavoni and others 2018; Raja and others 2016). (B) β-sheet aggregates have 
been stained with the fluorescent Thioflavin-S (Thio S) dye. Thio S staining was proposed to identify tau pathology in AD 
organoids (Raja and others 2016), though the precise molecular identity of the aggregates needs to be confirmed. (C) Enzyme-
linked immunosorbent assays (ELISAs) have been used to quantify secreted Aβ in the organoid medium (Choi and others 2014; 
Gonzalez and others 2018; Lee and others 2016; Lin and others 2018; Park and others 2018; Pavoni and others 2018; Raja 
and others 2016). (D) Protein levels of Aβ and p-tau have been compared in AD and control organoids by western blotting 
semiquantitative analysis (Choi and others 2014; Gonzalez and others 2018; Lin and others 2018; Park and others 2018; Raja and 
others 2016). See also Table 1.
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Question 6: How Reproducible Are 
the Data Generated from iPSCs?
If cerebral organoids are to be used as research work-
horses in the study of dementia, there is an implicit 
assumption that they can be prepared with a high degree 
of replicability. However, there are still many questions 
about whether different stem cell lines, and the organoids 
made from them, are sufficiently identical to allow com-
parisons to be made between them.
Many groups have generated patient-specific iPSC 
lines carrying mutations in the genes PSEN1, PSEN2, 
and APP (Arber and others 2017). While iPSC lines 
show some phenotype expression associated with AD 
after differentiation to brain organoids, iPSC line vari-
ability is an issue when identifying potential phenotypes. 
Functional variation between iPSC lines and clones 
relate to their capacity to differentiate to a particular 
germ layer or cell identity. These functional differences 
are underpinned by variation at the transcriptional and 
epigenetic levels, which may be due to genetic variation, 
level of reprogramming, copy number changes during 
reprogramming, parental cell origin, and/or culture con-
ditions (Ortmann and Vallier 2017; Polo and others 2010; 
Popp and others 2018; Schwartzentruber and others 
2018; Stadtfeld and others 2010).
Genome editing using homology-directed repair tech-
niques, such as CRISPR/Cas9 is a powerful tool for dis-
ease modelling. The use of precise genome editing can 
provide parallel cell lines that are genetically identical 
across the genome and differ only for a single disease-
causing or disease-relevant mutation. The ability to com-
pare gene-edited isogenic iPSC lines enables the 
investigation of molecular and cellular differences and 
strengthens tools for reverse genetic screening in iPSC 
disease models, increasing the likelihood that definitive 
disease profiles can be uncovered.
Because variation between and within iPSC lines is 
exceptionally important, and indeed imposes a limit on the 
generalizability of findings, there is great value in groups 
sharing the same lines experimentally, and comparing 
data for these lines both for similar and different experi-
ments. In essence, this is a test of our commitment to open 
science and collaboration. It is promising that initiatives 
are proposed to facilitate sharing iPSC lines from patients 
with different Mendelian forms of YOAD (Karch and oth-
ers 2018).
It is also important to consider the extent to which cel-
lular heterogeneity occurs during and after iPSC differen-
tiation, even when using “robust” differentiation protocols. 
Variation is observed both within one laboratory and 
between laboratories while using the same iPSC lines and 
following precisely the same differentiation protocols 
(Schwartzentruber and others 2018; Volpato and others 
2018). This highlights the need for comprehensive genetic 
and phenotypic analyses of differentiated iPSC-derived 
cell types to compare results obtained between laborato-
ries. When there is a conflict between data, whether within 
a laboratory or between laboratories, this may reflect 
authentic heterogeneity at the cellular level. Variability 
between iPSC lines, iPSC clones, and their derivatives 
shows that we need to treat data obtained with caution, 
and go back to the “whole person” for true validation of 
findings. This is not a simple task but it may be critical to 
our understanding of disease; for example, for AD it is not 
possible to truly confirm this diagnosis until the post mor-
tem brain pathology can be confirmed (Perl 2010). In liv-
ing patients amyloid imaging can be used as a biomarker 
for amyloid levels (Klunk 2011) but this is costly and not 
widely available (Vandenberghe and others 2013) and, as 
a result, is often not performed prior to inclusion of patient 
samples in stem cell studies.
Question 7: What about the 
Environment? Can We Model 
Modifiable Risk and Protective 
Factors for AD?
We frequently see the statement that about a third of the 
worldwide burden of dementia is attributable to modifiable 
risk factors in the environment (Livingston and others 2017; 
Norton and others 2014). It is therefore interesting to con-
sider whether organoids might offer a model to investigate 
these phenomena. This would be of value for it is not clear 
whether such epidemiologic estimates arise from mixing 
different forms of dementia together (in particular, VD and 
AD), or are due to the inherent promiscuity of the aged 
brain, pathologically speaking.
To model a complex protective factor would require 
that: (1) organoids develop a bona fide pathological pheno-
type (i.e., for AD, amyloidosis + tauopathy + neurode-
generation) and (2) a readout of global organoid “neuronal 
functionality” is possible.
To take a popular example, several studies suggest 
exercise may attenuate the rate of cognitive decline in at 
risk elders. Processes implicated include structural plas-
ticity in the hippocampus, upregulation of systemic brain-
derived neurotrophic factor, functional brain network 
change, and peripheral changes in immune-related cyto-
kines and myokines (Kivipelto and others 2018; Larson 
and others 2006; McEwen and others 2018; Muller and 
others 2017). Other studies dispute the beneficial effect 
of exercise on cognition (Young and others 2015). 
Disentangling the impact of exercise on dementia using 
human organoids, combining mechanical, biochemical, 
and genomic approaches, represents the precision medi-
cal science we hope to achieve.
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More ambitiously, to address the role of education as a 
protective factor for dementia, the “cognitive capacity” 
of an organoid could be estimated by its ability to habitu-
ate to a stimulus or even encode a stimulus pattern (i.e., 
learn) and then retain it over an interstimulus interval 
(i.e., memory)—ideas elaborated on in the next section. 
This represents a transition from the study of organoid 
structure to the study of organoid function.
Perhaps more attainable are models related to high 
prevalence risk factors. Smoking is the strongest environ-
mental toxin for dementia, responsible for an estimated 4.7 
million cases in 2010 (Norton and others 2014). As a first 
exploratory step, it would be interesting to model different 
levels of tobacco smoke concentration in an incubator, 
studying the effect on organoids for each type of dementia 
(AD, VD, DLB, and FTLD). Another group of candidate 
risk factors are metabolic: hypertension, type 2 diabetes, 
and obesity (Clark and others 2018; Gabin and others 
2017; Kivipelto and others 2018; Klimova and others 
2018; Pegueroles and others 2018). It may be possible to 
study neuronal and glial responses to aberrant metabolism 
by exposing organoids to varying levels of glucose and/or 
lipids. Other proposed environmental risk factors for 
developing AD include microbial infections, such as her-
pes simplex (Fulöp and others 2018; Lin and others 1996). 
Introducing an immune-related environment in organoids, 
by the use either of microglia or of macrophages, together 
with viral or bacterial pathogens, may allow the study of 
whether herpes simplex contributes to AD pathology.
Another potential insult to the brain is ischemia and 
hypoxia. There is a rich literature linking ischemia, 
hypoxia, and sleep disorders to AD pathology, offering 
circumstantial evidence (Valenzuela and others 2012). 
While the long-term objective is to create vascularized 
organoids perfusable with oxygen at different dissolved 
tensions, hypoxia could be modelled in a simple fashion 
by controlling atmospheric oxygen fraction over cultures. 
Low oxygen environments are known to affect neural 
stem cell proliferation, differentiation, and maturation 
(Xie and Lowry 2018). Whether the same holds for com-
plex multicellular organoids is a novel question, and any 
impact on the development of AD pathology is unknown.
Question 8: Can We Measure 
Cognition, and “Cognitive Reserve,” 
in Organoids?
Memory loss and cognitive decline are the mainstays of a 
clinical dementia diagnosis, often without data on the 
presence of neurodegenerative pathology. Studies on 
cognitive abilities show that early deposition of amyloid 
is related to worse cognitive and memory performance, 
even before individuals meet the clinical criteria for 
dementia (Rodrigue and others 2012). Given that 
amyloid load does not directly correlate with symptoms 
(Hedden and others 2013) it is not clear whether this is 
the direct result of amyloid itself or an indirect effect of 
other cell biological and degenerative processes. The bio-
logical processes underlying such cognitive impairment 
are manifold, and most often include loss of connections 
between neurons (Dorostkar and others 2015). Such dis-
arrayed communication breaks down the synchronized 
activity of entire areas, with working memory function 
quickly lost (Morrison and Baxter 2012). Being able to 
study the biological mechanisms behind cognitive decline 
is therefore essential for an in vitro dementia model. 
While histological tools exist to assess neurodegenera-
tion, synaptic dysfunction, or alterations in neuronal/glial 
interactions, real value would come from gaining this 
information from living tissue, with the advantages of 
longitudinal interrogation.
There is clearly a growing need to develop technolo-
gies that can reliably measure neuronal functionality 
within organoids. Functional assays, such as calcium 
imaging (Fig. 6) or microelectrode arrays (Fig. 7) can be 
used to measure neuronal activity and formation of syn-
chronous neuronal networks, and have already been suc-
cessfully applied to iPSC-derived organoids (Quadrato 
and others 2017). An important challenging factor to con-
sider is the time needed for neurons to mature and form 
networks within the organoids, which may take several 
months (Quadrato and others 2017). It is not currently 
clear how the organoids “age” or “mature” over time, in 
terms of their functional activity. This process needs to be 
characterized so that we can understand whether changes 
in functional outputs are disease related or an artefact of 
chronic long-term culture conditions. Other complimen-
tary approaches may be to optically measure calcium 
transients or changes in membrane potentials within a 
multitude of neurons in real time and across the whole 
three-dimensional structure, or measuring neurotransmit-
ter levels, such as glutamate, generated within the organ-
oids (Nasr and others 2018; Sloan and others 2018). A 
major challenge is to develop live imaging tools and elec-
trical recording techniques that overcome the z-plane 
depth limitation of organoid models. Another challenge is 
to develop organoid-specific data analysis tools that 
accurately model the structural and functional informa-
tion that can be matched with clinical data.
On the flip side to memory loss and cognitive decline, 
it would also be valuable to use organoids to model and 
measure cognitive reserve—a concept often invoked to 
explain the disconnect observed in ~30% of older persons 
who express suprathreshold levels of AD pathology in 
terms of amyloid deposition (whether at post mortem or 
by in vivo imaging) but do not exhibit dementia (Stern 
and others 2018). In essence, cognitive reserve refers to 
the adaptability, efficiency, and flexibility of the brain 
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and its cognitive processes in the face of stressors such 
that overall function is maintained and protected (Stern 
and others 2018). Determinants of greater cognitive 
reserve include lifelong mental stimulation and challenge, 
including education, occupational complexity, and intel-
lectual leisure pursuits. Organoids may be useful in mod-
elling such determinants by measuring neuronal firing 
activity, particularly in synchronous neuronal networks, 
in response to different levels of stimulation. Currently, it 
is difficult to assess how measurements of function in 
organoids scale up to measurements in whole brains. 
A theoretical approach that could be used is the 
Perturbational Complexity Index that was developed and 
tested in healthy subjects and coma patients (Casali and 
others 2013). The technique uses transcranial stimulation 
to assess consciousness that is independent of sensory 
processing. However, the issue of consciousness in brain 
organoids leads to significant ethical implications (see 
Question 10). At present there is no evidence from pub-
lished studies that brain organoids exhibit consciousness, 
and in fact, single cell analyses suggest brain organoids 
show a lack of maturity (Bhaduri and others 2020).
Question 9: Can Organoids Be Used 
for Drug Discovery?
There is a strong hope that organoids will be of immedi-
ate value for use in drug screening and development. 
Figure 6. Functional assessment of cerebral organoids by calcium imaging. (A) A representative image of a culture derived from 
a YOAD cerebral organoid loaded with the ratiometric calcium indicator Fura2-AM. A 9-month-old organoid was seeded onto a 
glass coverslip for Ca2+ imaging. The image shows the overlay of 340 nm and 380 nm channels; each colored circle corresponds 
to a region of interest (ROI) represented in (B). When Ca2+ binds to the indicator, fluorescence at 340 nm increases, while 380 
nm fluorescence decreases. The 340/380 ratio is thus used as a measurement of Ca2+ responses to drugs or agonists or to assess 
spontaneous activity. (B) Relative change in fluorescence intensity over time of specific ROIs from (A) using Fura2-AM. Neurons can 
be stimulated with chemicals that are perfused into the bath chamber and the Ca2+ responses recorded. The culture was exposed 
to the excitatory neurotransmitter glutamate (20 µM; perfusion indicated by the horizontal black bar) to elicit a Ca2+ response, 
followed by high K+ (60 mM; perfusion indicated by the horizontal black bar) to mimic membrane depolarization. Responses may be 
fast or slow transient increases or prolonged increases that do no return to baseline within the timeframe of the experiment.
Figure 7. Electrophysiological assessment of cerebral 
organoids by microelectrode arrays. (A) Organoids can be 
seeded in well chambers (B) on top of regularly spaced arrays 
of electrodes. (C) Organoids are electrically active; shown are 
recordings from two different organoids at 25 kHz, whereby 
spikes identify electrophysiological activity. The recordings 
show a difference in spontaneous activity from the two 
organoids, which can be quantified via various parameters, 
such as spike amplitude and firing rate. Experiments can be 
designed to compare organoid responses to chemical or 
electrical stimulation and can provide information on neuronal 
network dynamics and the formation of functional circuits.
12 The Neuroscientist 00(0)
However, while human brain organoids have potential to 
model AD and other dementias, it is not yet clear whether 
they can be adapted for applications in drug discovery.
The promise of organoids lies in their ability to model 
complex processes and it is precisely this complexity 
that is at odds with the industrial practice of targeted 
drug discovery. Typically, drug screens adopt a reduc-
tionist approach, making use of simple, direct molecular 
assays in the initial chemical screening phase to identify 
active “hits” from libraries of chemical scaffolds. 
Organoids are therefore unlikely to be useful at the initial 
chemical library screening stage. Rather, they may come 
into their own for identification of biochemical pathways 
or specific molecules that modulate the course of dis-
ease, a research process often termed “target identifica-
tion,” which precedes the commitment to a targeted drug 
discovery campaign (Fig. 8).
Organoids will also have important roles to play in 
selection of the most biologically active compounds in 
the later stages of lead development, when more costly, 
complex, and informative biological models are justifi-
able and valuable. Such models also have the potential 
to identify opportunities for repurposing approved 
drugs, and ultimately provide the means to personalize 
therapy by identifying drugs that are most effective at 
reversing the pathology in organoids produced from 
patient-derived iPSCs.
It is tempting to suggest that a complex disease 
requires a complex model to identify useful hits, even 
during the early stages of hit identification. Can the 
potential of organoids be harnessed at this early stage, 
prior to target identification, using a “phenotypic” screen-
ing process? This will depend on whether a disease-rele-
vant assay (or combination of assays) is replicable (as 
discussed above) and is sufficiently sensitive to measure 
drug activity. Quantitative phenotypic screening assays 
need to be devised that are specifically designed for 
organoid cultures and address these issues, particularly in 
relation to reproducibility.
Question 10: What Are the Ethical 
Issues and Community Expectations 
Around Brain Organoids?
When stem cells were first derived from human embryos 
that had been stored for in vitro fertilization but were no 
longer wanted for reproduction, there was a great deal of 
ethical debate; some people with religious objections to 
the destruction of embryos opposed the generation of 
embryonic stem (ES) cells. However, most stem cell 
research today is performed using iPSCs, which do not 
raise the same level of ethical concern. Nevertheless, 
human ES cells are still regarded as being the “gold stan-
dard” for potency, and the International Society for Stem 
Cell Research has established guidelines for researchers, 
clinicians, and funding agencies in this regard (Daley and 
others 2016).
The fact that the specific issues around embryo 
destruction have been solved by scientific advances does 
not mean that there are no remaining ethical concerns 
voiced by the community (Allum and others 2017; 
Bredenoord and others 2017; Chalmers and others 2017; 
Stadelmann and Torgler 2017; Shepherd 2018). Recent 
discussions around the ethical issues of brain organoids 
describe consciousness as a moral limit of brain organoid 
research (Bayne and others 2020; Koplin and Savulescu 
2019; Sawai and others 2019). While most people favor 
the use of stem cells for medical research and clinical 
care, they add a strong proviso: the public must be 
involved in open and frank discussions around ethical 
issues, such as privacy and consent, and the way organ-
oids are derived and treated (Farahany and others 2018).
Figure 8. Schematic showing opportunities for the use of brain organoids in the drug development pipeline. In particular, stem 
cell–derived culture models have the potential to improve lead optimization for “formal preclinical” and clinical development.
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It is difficult to obtain informed consent to collect, 
study, and store biological material from people with 
dementia, although a common sense approach combined 
with information from people with early stages of 
dementia indicate that many of them would wish to par-
ticipate (Howe 2012; Slaughter and others 2007). 
Because stem cell and organoid research is advancing 
rapidly, it is not possible to predict all of the ways in 
which cells might be used in future. The coalescence of 
these two concerns raises complications for those using 
organoids for dementia research, and it is imperative 
that researchers engage with those living with dementia 
and their families and carers (Pachana and others 2015; 
Ries and others 2017). It may be possible to use a 
research equivalent of an “advanced care directive,” 
where a person consents to future research relevant to 
dementia, prior to cognitive decline.
Since family history is a well-known risk factor, chil-
dren of persons with AD will be a group of highly moti-
vated individuals who wish to participate in research, 
just as soon as there is hope of an effective intervention. 
Because of this, and unlike many situations in medical 
research, cell donors should be reidentifiable, particu-
larly if they carry the major risk allele APOE4. This 
leads to a range of ethical (and legal) issues around de-
identifying data, sharing of data between research 
groups (Isasi and others 2014), and whether there is a 
responsibility to inform participants of their genetic risk 
status (Milne and others 2018; Timmermans and 
Buchbinder 2010). It is important to encourage research 
into the effects of revealing high-risk genotypes to 
asymptomatic adult children of people with AD, in the 
context of availability of direct-to-consumer genotyping 
(Green and others 2009).
The expectation of the community that they will be 
consulted about research using stem cells also involves a 
major commitment to education, both about dementia 
and about stem cell science (King and others 2014). On 
an issue as critical and costly as this, it may be appropri-
ate for national research bodies, such as the National 
Institutes of Health in the United States, the Medical 
Research Council in the United Kingdom and the National 
Health and Medical Research Council of Australia to play 
a major role in initiating both community education and 
public discussion on dementia.
Final Thoughts
Caveats and Challenges: Whilst organoids provide 
opportunities for disease modelling, the current literature 
suggests cell maturation remains limited due to high lev-
els of cellular stress (Bhaduri and others 2020). Future 
work needs to consider how to progress model systems to 
better recapitulate the spatiotemporal dynamics of 
differentiation and how to deal with the impact of cellular 
stress during long term cell culture. Addressing these dif-
ficulties is essential to improve our understanding of the 
model systems and the diseases they represent.
Opportunities: Stem cells and organoid technology will 
enable us to ask, and maybe even answer, some of the 
fundamental questions about pathological processes and 
risk associations for dementia, as well as neurodegenera-
tive diseases more broadly (Lambert and others 2013). 
The most direct route is for stem cell scientists and clini-
cians to work closely together, in a manner where the 
technological advances and knowhow of scientists are 
guided by the most perceptive clinical insights and the 
most pressing health needs.
This approach has led to successes for other diseases. 
Some serious diseases (such as measles and polio) have 
been virtually eliminated, others (such as breast cancer or 
HIV in many countries) are much less likely to kill and 
are amenable to treatment, while conditions such as car-
diovascular diseases (myocardial infarcts and strokes) 
still are common, but have been displaced to occur more 
often in the elderly. These transformational medical 
advances, be they environmental, behavioral, or pharma-
cological, are based on research.
Many who have worked on diseases outside the brain 
are surprised at how little we know about the fundamentals 
of Alzheimer disease and other causes of dementia. We 
eagerly await data showing whether pre-symptomatic 
removal of amyloid from the brain delays the onset of 
Alzheimer dementia, particularly if initiated prior to symp-
toms. At this stage, iPSC lines and cerebral organoids may 
reflect some of the clinical features of the patients from 
whom they were obtained, particularly with respect to 
pathology and etiology. If this proves to be true and techni-
cal variation can be controlled, then cerebral organoids 
may become a very powerful research tool for the study of 
dementia. There is room for optimism, but also a need for 
caution, with an assurance that rigorous and replicable 
hypothesis-driven experiments can translate back to real 
people with real-world clinical problems.
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